Literature DB >> 20202604

Taxanes and anthracyclines in early breast cancer: which first?

Hans Wildiers, Kathleen Forceville, Robert Paridaens, Heikki Joensuu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20202604     DOI： 10.1016/S1470-2045(10)70025-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

1.  Shorter course of trastuzumab: Caveat emptor.

Authors:  Ajit Venniyoor
Journal:  Indian J Med Paediatr Oncol       Date:  2011-01

2.  Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer.

Authors:  Ashok K Vaid; Aseem Khurana; Devender Sharma; Dheeraj Gautam; Jyoti Wadhwa; Rajiv Agarwal; Kanchan Kaur; Jyoti Arora; Kush Gupta
Journal:  World J Oncol       Date:  2020-05-14

3.  Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.

Authors:  Junjie Li; Keda Yu; Da Pang; Changqin Wang; Jun Jiang; Suisheng Yang; Yunjiang Liu; Peifen Fu; Yuan Sheng; Guojun Zhang; Yali Cao; Qi He; Shude Cui; Xijing Wang; Guosheng Ren; Xinzheng Li; Shiyou Yu; Pengxi Liu; Xiang Qu; Jinhai Tang; Ouchen Wang; Zhimin Fan; Guoqin Jiang; Jin Zhang; Jiandong Wang; Hongwei Zhang; Shui Wang; Jianguo Zhang; Feng Jin; Nanyan Rao; Binlin Ma; Pingqing He; Binghe Xu; Zhigang Zhuang; Jianfeng Wang; Qiang Sun; Xiaofeng Guo; Miao Mo; Zhimin Shao
Journal:  J Clin Oncol       Date:  2020-04-10       Impact factor: 44.544

4.  Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.

Authors:  W Janni; N Harbeck; B Rack; D Augustin; J Jueckstock; A Wischnik; K Annecke; C Scholz; J Huober; T Zwingers; T W P Friedl; M Kiechle
Journal:  Br J Cancer       Date:  2016-03-31       Impact factor: 7.640

5.  A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.

Authors:  Hiroshi Ishiguro; Norikazu Masuda; Nobuaki Sato; Kenji Higaki; Takashi Morimoto; Yasuhiro Yanagita; Makiko Mizutani; Shoichiro Ohtani; Koji Kaneko; Tomomi Fujisawa; Masato Takahashi; Takayuki Kadoya; Nobuki Matsunami; Yutaka Yamamoto; Shinji Ohno; Toshimi Takano; Satoshi Morita; Sachiko Tanaka-Mizuno; Masakazu Toi
Journal:  Breast Cancer Res Treat       Date:  2020-03-13       Impact factor: 4.872
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.